Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNV2197944 vs placebo in neuropathic pain due to diabetic peripheral neuropathy
2013-000407-16Phase 2Completed
- Sponsor
- Convergence Pharmaceuticals
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CNV-2197944 in diabetic polyneuropathy (DPN) (2 arms), sponsored by Convergence Pharmaceuticals. Primary endpoint: Change in average daily neuropathic pain score. Started Mar 2013; status: completed.
02
Drugs
CNV-2197944
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2013-000407-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000407-16.